This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Disease Modifying Genes in Severe Asthma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00212537
First received: September 19, 2005
Last updated: February 1, 2017
Last verified: February 2017
  Purpose
Gene and protein bank to study disease modifying and susceptibility genes and proteins in urban patients with asthma.

Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Other
Official Title: Disease Modifying Genes in Severe Asthma

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • To recruit and characterize a cohort of subjects with asthma who reside in a high pollution, high asthma risk neighborhood [ Time Frame: five yeARS ]

Biospecimen Retention:   Samples With DNA
The total amount of blood drawn is approximately 5 tablespoons (75 ml). The blood sample will be processed to isolate "genetic material" (mainly DNA, RNA and protein). This genetic material will be used to try to identify the "genetic factors" or genes that a person inherits that make him or her more likely to develop asthma. The blood is used to test for allergies to weeds, trees, insects and molds (RAST) and a complete blood count.

Estimated Enrollment: 2000
Study Start Date: April 2002
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All individuals approached for participation in the Research Registry shall be able to read or comprehend English. Since participation in the Research Registry does not involve a risk of physical harm, women of childbearing potential will not be queried as to pregnancy status or tested for pregnancy unless they are requested to undergo a methacholine challenge test. There are no additional inclusion/exclusion criteria.
Criteria

Inclusion Criteria:

  • Ages 18 and above

Exclusion Criteria:

  • Greater than 10 pack year tobacco history
  • Lung diseases other than asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212537

Locations
United States, New York
NYU School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Investigators
Principal Investigator: Joan Reibman, MD NYU School of Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00212537     History of Changes
Other Study ID Numbers: H9698
Study First Received: September 19, 2005
Last Updated: February 1, 2017

Keywords provided by New York University School of Medicine:
Asthma and normal

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 21, 2017